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Abstract
Breast cancer (BC) is a heterogeneous disease encompassing a wide array
of categories of cell subpopulations, molecular aberrations and different
clinical and pathological behaviors. The most challenging obstacle faced
by clinicians is represented by a full understanding of such heterogene-
ity and processes of resistance induced after the administration of anti-
cancer drugs. For such reasons, BC is classified according to a number of
several clinico-pathological and molecular factors. Over 20 histologic spe-
cial types of BC are recognized by The World Health Organization (WHO)
[1].Special types of BC account for approximately 20% of all newly di-
agnosed cases. In spite of these mostly morphohistological classifications,
treatment decisions are mostly guided by the size of the primary neoplasm
at presentation, the involvement of locoregional lymph nodes, the status
of few, actionable biomarkers such as estrogen and progesterone receptors
and the amplification of the ERBB2/HER2 gene, as well as by the degree of
differentiation and the proliferation index of cancer cells. The morphology
of BC cells and their histological architecture, accounting for the identifica-
tion of a special type, is almost not taken into account in clinical decisions
by most guidelines [2]In this thesis, I focused on the molecular character-
ization of special types of BC, with the purpose of identifying potential
novel biomarkers of diagnosis, prognosis, and therapeutical prediction in
such large, but in part neglected, class of tumors. Out of my research, I
published two original scientific papers. The first one describes the ge-
nomic landscape of four special types of BC: invasive lobular carcinoma
(ILC), mucinous carcinoma (MUC), micropapillary carcinoma (MPC) and
metaplastic carcinoma (META). The second one focuses on the molecular
comparison between metaplastic carcinoma and uterine carcinoma, stem-
ming from their similar histology and clinical behavior.
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Breast cancer (BC) is a heterogeneous disease encompassing a wide set
of categories of cell subpopulations, molecular aberrations and different
clinical and pathological behaviours. Thereforse, BC is classified accord-
ing to a number of several clinico-pathological and molecular factors. In
this section, molecular and histologic characterization is explored.
1.1 Molecular characterization of breast cancer
In 2000, the pioneering work of Perou et al. [5] and Sørlie et al. [6]
demonstrated that BC can be subdivided into at least four intrinsic molec-
ular subtypes, that reflect differences in phenotype, prognosis and treat-
ment response. These seminal studies analyzed the gene expression dif-
ferences through cDNA microarray approach. Based on the results, the
Authors discovered that their classification was mostly driven by the ex-
pression of three membrane receptors, namely the estrogen receptor (ER),
the progesterone receptor (PR) and the epidermal growth factor receptor 2
(ERBB2/HER2), as well as by the regulation of cell proliferation (summa-
rized by the proliferation-related protein Ki67). Collectively, ER and PR
are considered the main hormone receptors (HRs) in BC. These elements
represent one of the pillars for BC classification as of today. In clinical
practice, the activity of HR/HER2/Ki67 is evaluated by a combination of
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immunohistochemistry (IHC) and in-situ hybridization (ISH), which are
considered sufficient and reasonably robust to frame the clinically relevant
molecular characteristics of BC and drive therapeutic choices. Neverthe-
less, due to the increasing awareness of the huge interpatient variability
of BC, the demand for more refined and specific classification of BC has
led to the development of the so-called multigenic assays such as: PAM50
(50 genes), Mammaprint (70 genes) and Oncotype DX (21 genes) [7-9], al-
lowing for the simultaneous evaluation of the status of dozens of genes.
These multigenic assays were designed to identify, with the technologies
available in the first years of the 2000s, early stage BC cases at higher risk
of recurrence and thus deriving greater benefit from adjuvant chemother-
apy. The four intrinsic molecular subtypes identified by Perou et al. [5],
and consistently showing biological and clinical coherence over the last
twenty years are: luminal A, luminal B, Basal-like, HER2-enriched and
normal-like.
•LUMINAL A is the most common intrinsic subtype [10]. According to
the current guidelines, luminal A is characterized by the expression
of ER (  1%) and/or PR (  20%), poor expression of HER2 ( 30%)
and low levels of Ki67 [11]. Generally, Luminal A cancers are low-
grade, and are associated to good prognosis, slow growth and lim-
ited lymph node involvement [12]. The positive status of HR makes
luminal A targetable by endocrine therapies (ETs) such as aromatase
inhibitors (AI), or selective estrogen receptor degraders (SERDs) [13].
•LUMINAL B is responsible for 20-30% of invasive BC [10]. This subtype
is characterized by ER ( 1 %), PR (<20% or any) and HER2 ( 10%)
and high level of Ki67 (  20%, although IHC cutoffs are varied and
there is no universal consensus) [11]. Compared to luminal A, lu-
minal B BC shows a higher growth rate and worse prognosis with
higher chance of local and distant recurrence [12]. It is considered
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the most aggressive form of HR+ BC and does not always derive
benefit from ETs, although in the absence of biomarkers of primary
resistance, ETs are offered to all patients falling in this category [14].
The main molecular differences between the two luminal types is
represented by the increased activity of genes involved in the prolif-
eration process (NSEP1, CCNE1) and activation of PI3K pathway in
luminal B cancers [15].
•BASAL-LIKE BC constitutes from 10 to 20% of BC [10]. It is character-
ized by the lack or very low levels of expression of ER, PR and HER2
(< 10%), but high proliferation indices (ki67 > 30% with few excep-
tions, such as apocrine BC) [11]. For this reason, they can be defined
as triple-negative BC (TNBC), although there is no complete over-
lap between TNBC (which is an immunohistochemical definition of
BC) and basal-like BC (which is deemed so by gene expression pro-
filing). Basal-like cancers are aggressive and show a high risk of both
local and distant recurrence, especially in the first few years after di-
agnosis [16]. Their diagnosis subtends a generally poor prognosis.
More recent studies have focused on the molecular profiling of this
category of BC, further identifying several subclasses: basal-like 1
and basal like-2 (BL1 and BL2) display TNBC gene expression pat-
terns but a different immune activity; luminal androgen receptor-
like (LAR) is characterized by specific a specific gene expression pro-
file of androgen metabolism; immune-modulatory class (IM) has al-
tered activity of immune related signatures; two subtypes are asso-
ciated to an enrichment of the EMT (epithelial mesenchymal transi-
tion) pathway, and are called mesenchymal (M) and mesenchymal
stem-like (MSL) [17]. The stability of these further classifications has
been rediscussed recently, but its overall validity holds true [18]. In
the clinical practice, TNBC/basal-like BC represents a real challenge
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for its molecular and morphological heterogeneity and the current
lack of targeted therapies [19].
•HER2-ENRICHED BC is responsible for 15% to 20% of cases [10]. Pos-
itivity of HER2 is usually evaluated: 1) in IHC as strong/complete
membrane staining (score 3+) in at least 10% of cancer cells or 2)
in ISH, where the HER2/CEP17 ratio (  2) and an average ERBB2
gene copy number (  4) determine the amplification of HER2 [20].
In clinical practice HER2 status is assessed by IHC and ISH in case of
intermediate protein staining. HER2-enriched cancers are associated
to a high proliferation phenotype and have a poor natural history.
However, HER2+ cancers can be successfully treated with targeted
therapies focusing on the HER2 protein complex (Trastuzumab, Per-
tuzumab, Lapatinib, Neratinib) [19], which have largely reversed
such prognosis in clinical practice over the last twenty years [21].
1.2 Histological types of breast cancer
BC can be classified according to the tissue morphology. The main deter-
minant of invasiveness consists in defining whether the malignancy is cir-
cumscribed to the epithelial part of the breast (so-called in situ BC, which
is a misnomer for a premalignant lesion), or extents to the stroma, and if
the tumor invades ducts or lobes [22]. However, in clinical practice, rather
than the precise location, several factors such as cell type morphology, can-
cer architecture, secretion activity and IHC define the histological nature
of the tumor. The most common histological form of BC is the invasive
ductal carcinoma (IDCs). IDCs can be classified as ‘not otherwise speci-
fied’ (IDS-NOS) or ‘no special type’ (IDC-NST), due to the absence of pe-
culiar morphological characteristics. In fact, IDC-NST is a heterogeneous
disease entity, and shows a wide range of clinical behaviors. In contrast,
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IDCs can be classified as of pertaining to a ‘special type’, whenever the
cancer tissue presents distinctive characteristics. Histologic special types
of BC account for up to 20% of all BC cases. The most common forms are:
invasive lobular carcinoma (ILC), metaplastic carcinoma (META), muci-
nous carcinoma (MUC), micropapillary carcinoma (MPC).
•INVASIVE LOBULAR CARCINOMA (ILC) is the second most common of
distinct BC, representing approximately 10-15% of newly diagnosed
BC [23]. It is characterized by the infiltration of discohesive cordon-
structured neoplastic cell in the lobules wall and in the mammal tis-
sue and by the loss of E-caderin (CDH1) staining in 95% of cases.
ILC is more common in older woman, tending to occur later in life
than IDC [24], is less sensitive to chemotherapy, may respond better
to Ais, and has a tendency to relapse later than IDC and in unusual
sites, such as submucosal tissues, uterus and eye socket [25].
•METAPLASTIC CARCINOMA (META) is characterized by a predominant
component of metaplastic differentiation. It is a poorly differenti-
ated tumor, showing heterogenous morphological features, contain-
ing ductal component mixed with squamous/spindle cells or chon-
droid cells. Often it is associated with lymph node involvement and
has an aggressive behavior. It comprises about 1% of BC, occurring
most likely after menopause [24].
•MUCINOUS CARCINOMA (MUC) , also known as mucoid carcinoma,
represents about 4% of BC. It has been associated to a better prog-
nosis. MuC is characterized by abundancy of extracellular mucins
that cluster around tumor cells [24].
•MICROPAPILLARY CARCINOMA (MPC) represents about 6% of BC [24].
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It is one of the most aggressive special types and is associated to un-
favorable prognosis due to the extremely early and frequent involve-
ment of axillary lymph nodes [26].
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Chapter 2
Next generation sequencing: an
overview
In the last decade, the tremendous advances of massively parallel sequenc-
ing (MPS) technologies have allowed for the analysis of large case sets
with a significant decrease in costs, an improvement of turnaround times,
and an increase in sequencing accuracy. Nowadays, oncologists rely on
MPS for clinical purposes as well as for research. In this chapter, I de-
scribe the most common aberrations of BC with potential or practical clin-
ical consequences.
2.1 Oncogene and tumor suppressor genes
Cancer-related genes can be divided into two classes according to the dif-
ferent role played in the biology underlying a specific cancer type. The
first class is that of proto-oncogenes. This class consists of genes coding
for proteins involved in cell cycle regulation, cellular differentiation, and
cell death. The transition from proto-oncogene to oncogene may lead to
the neoplastic phenotype, especially when several oncogenes act at the
same time. Bona fide examples of oncogenes in BC are ErbB2, MYC and
PIK3CA. The transition of a proto-oncogene to a cancer driver gene occurs
upon even slight modifications of its wild-type form such as: 1) Mutations
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within the body of the proto-oncogene or within its regulatory region: the
mutation may lead to enhancement of the coded protein activity or to an
abnormal active regulation. 2) Altered number of genetic copies of the
proto-oncogene, with a resultant overproduction of its protein product. 2)
Increment of the concentration of a protein, caused by altered gene expres-
sion levels, or abnormalities in the protein stability, causing a prolonged
activity in the cell. 3) Genome rearrangement such as fusion and translo-
cation. The second class of cancer genes is that of tumor-suppressor genes
(TSG). A TSG codes for a protein involved in fundamental biological pro-
cesses during cell division (e.g. repairing DNA error) or apoptosis. When
a TSG is mutated, it results in its inactivation, leading to the development
of neoplasia. Contrary to oncogenes that are characterized by a ‘gain of
function’ alteration, TSGs are affected by a reduction or a ‘loss of function’.
Another fundamental difference between oncogenes and TSGs is summa-
rized by the so-called Knudson’s double-hit hypothesis. According to this
hypothesis, both alleles of the same gene must be affected before an effect
is manifested, while only one gene must be activated before it manifests
its obnoxious. In other words, as long as one of the alleles of the gene is
not damaged, its function is preserved. The most known TSGs in BC are
BRCA1, BRCA2, PTEN, TP53.
2.2 Gene Mutations
DNA sequencing has allowed to determine the entirety of an organism
genome. In other words, it is possible to know the exact status (mutated
or wild-type) of each gene of an individual at a given time. However, in
clinical practice such gigantic amount of information is limited to a hand-
ful pool of genes with an established association with cancer disease. For
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this reason, the last decade has seen the rise of the so-called targeted se-
quencing. Targeted sequencing consists in analyzing specific genomic re-
gions known or suspected to play a putative role underlying a specific
phenotype or a disease. In BC, approximately 50 genes are considered
meaningful for clinical purposes. This list of genes comprises both onco-
genes and TSGs such as BRCA1/2, TP53, PIK3CA, ESR1, PTEN, PALB2,
GATA3, KMT2C, NCOR1, AKT1, NF1, CDH1, and RB1. In recent stud-
ies, a number of novel genes with likely oncogene or TSG roles, includ-
ing TBX3, RUNX1, CBFB, AFF2, PIK3R1, PTPN22, PTPRD, SF3B1, and
CCND3, have been reported [27, 28]. One of the most known TSG in
BC are the BRCA genes. BRCA1/2 play a key role in the regulation of
the cell cycle, cell proliferation, cell differentiation, and, importantly, in
the process of DNA damage repair (DDR) by homologous recombination.
DDR maintains nucleic acid sequence accuracy during DNA replication
and transcription, as well as upon cell exposure to potentially harmful
external agents [29]. Loss of function of BRCA genes results in homolo-
gous recombination repair deficiency (HRD), one of the most well-known
molecular mechanisms underlying cancer development and progression.
Another recurrent mutated gene in cancers is TP53. Mutations affecting
TP53 lead to a loss of function effect [30], and in the context of BC, are
frequent in estrogen receptor (ER)-negative breast cancer. One of the most
frequently mutated oncogenes in HR+ BC is the Phosphatidylinositol-4,5-
Bisphosphate 3-Kinase Catalytic Subunit Alpha, PIK3CA. PIK3CA codes
for the p110a subunit of PI3K. PIK3CA mutations within the helical and
the kinase domains cause a positive activation of PI3K pathway, result-
ing in uncontrollable cell proliferation [31]. Similar biological effects re-
sult from PTEN loss-of-function [32], as this tumor suppressor protein is a
negative regulator of PIK3CA. Another clinically relevant and frequently
mutated gene in BC is ESR1. Mutations affecting ESR1 cause a constitutive
activation of the Estrogen Receptor alpha (ERa), which results in enhanced
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cell proliferation and resistance to endocrine therapy in ER-positive breast
cancer [33]. Genomic analysis highlighted that ESR1 mutations are found
almost exclusively in metastatic HR+ BC rather than in primary tumors
and have paved the way for the evaluation of ESR1 mutational status for
its potential clinical utility [34,35]. ESR1 mutations are of special interest,
because they are a proof of principle of the evolutionary mechanism of
cancer escape under treatment pressure.
2.3 Gene Amplifications/Deletions
Copy number variation (CNV) represents a type of structural variation in
which genomic sections are repeated altering the hypothetical physiolog-
ical number of alleles of a gene. CNV encompasses two types of mod-
ification, amplification and deletion. In BC, CNVs represent one of the
most predominant genomic modifications of clinical relevance [36]. An
example of a CNV of prognostic and therapeutic value is the amplifica-
tion of the HER2 (ERBB2) gene [37], located on the chromosome 17 (q12).
ERBB2 amplification causes the overexpression of the tyrosine kinase re-
ceptor HER2, which acts as a positive trigger for the downstream activa-
tion of PI3K/AKT and MAPK pathways. These, in turn, play a crucial role
in tumor cell proliferation and survival. Patients with HER2-enriched BC
benefit from the use of anti-HER2 monoclonal antibodies. The standard
assessment of CNV is based on quantitative PCR or ISH, but such tech-
niques only allow to detect specific DNA sequences. Multi-target CNV
evaluation can be performed using comparative genomic hybridization
(CGH) technique and whole genome single nucleotides polymorphism
(SNP) array, or alternatively, using NGS approaches. Besides ERBB2, other
potentially actionable genes often amplified in BC are NOTCH1/2/3, MYC,
FGFR1/2, and EGFR. The most common deletions found in BC involve
PTEN, CDH1, CDKN2A/2B, RUNX1/CBFB, RB1, TP53, and INPP4B [27].
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2.4 Genomic Rearrangements
Another type of structural modification is the rearrangement of the genome.
Genomic rearrangement results from translocation of DNA regions that
lead to the formation of fusion genes. Although fusion genes have been
mainly investigated in hematological malignancies, such as leukemias and
lymphomas (e.g. BCR-ABL1 fusion protein in chronic myeloid leukemia),
they have also been detected in solid tumors, such as EML4-ALK fusion in
lung adenocarcinomas [38]. Therefore, fusion gene detection is becoming
a key aspect of genomic investigation in BC research. Genomic rearrange-
ments can play an important role in cancer development and progression,
and they may be clinically actionable genomic alterations with potential
therapeutic impact. The standard assessment for the presence of fusion
genes consists in FISH and IHC techniques, which might not be sufficient
for multiplex analysis and more comprehensive tumor profiling. Nowa-
days, NGS has been implemented for detecting putative fusion genes and
for finding potential new rearranged genomic regions [39]. In BC, few fu-
sion genes have been detected so far [40]. Large genomic rearrangement
involves for example BRCA1/2, MAGI3-AKT3, FGFR3-TACC3, BCL2L14-
ETV6, and ESR1-CCDC170. For example, MAGI3-AKT3 fusion results in
the constitutive activation of AKT kinase, and it is now considered a pos-
sible target for ATP-competitive AKT small-molecule inhibitors [41]. Re-
current rearrangement found in ER+ BC is ESR1-CCDC170 fusion (6–8%)
of luminal Bs [42]. Currently, therapies able to target this specific type of
chimeric protein product are not yet available and elucidative studies are
expected to shed light on the various ESR1 fusions, as well as their role in
endocrine resistance of primary and metastatic ER+ BC. Finally, a family
of rearrangements, namely the NTRK fusions, is believed to be an action-
able genomic target in different cancer types including BC and has been
the first genomic aberration to receive an agnostic approval of target drug,
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i.e. its finding allows for selective inhibitors to be administered indepen-
dently of the tissue of origin of the neoplasm [43]. However, its frequency
in BC is very low.
2.5 Genomic signatures
A gene signature is defined as the combined action of a set of altered
genes, or genes module, the effect of which modifies critical aspects of
the cell. This process may occur as a result of abnormal biological process
or pathogenic condition. An example of gene signature is the mutational
genomic signature, that represents the effect of mutational processes on
cancer due to the exposure to exogenous or endogenous mutagens. SNVs
and chromosome CNVs are examples of mutational patterns that may af-
fect genes involved in fundamental biological mechanisms. In cancer re-
search, the mechanisms of DNA damage response, DNA repair, and DNA
replication [44] are among the most relevant ones from a biological and
clinical point of view. In BC, homologous recombination deficiency (HRD)
plays a fundamental role [45]. HRD is strongly associated with the loss of
function of BRCA1/2, RAD51, PALB2 genes. HR is one of the main mecha-
nisms of DNA repair after damage-caused double-strand breaks (DSBs).
HRD detection is carried out on several different technologies such as
array-based comparative genomic hybridization (aCGH) and NGS. HRD
has gained the attention of the clinical and research community because
it is more and more considered as a valuable biomarker for the response
to DNA-damaging agents such as platinum agents and anthracyclines, as
well as to PARP inhibitors [46]. Currently, two FDA-approved assays ex-
ist that allow to detect HRD along with other important signature, the
telomeric allelic imbalance (TAI) [47], and large-scale transition (LST) [48].
Another critical signature is the tumor mutation burden (TMB), which is
defined as the number of mutations per megabase (mut/mb) in a given
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neoplastic specimen [49-50]. It has been already demonstrated that TMB
acts as a clinically useful biomarker for immune checkpoint inhibitor (ICI)
response, independently of PD-L1 expression, in NSCLC, melanoma, and
bladder cancer [51,52]. This phenomenon can be traced back to the intrin-
sic nature of the TMB: tumors with high values of TMB are more likely to
express new immunogenic antigens. This, in combination with ICIs, can
lead to an activation of the immune system against cancer cells [53]. Al-
though BC seems less immunogenic compared to other malignancies [54],
it has been demonstrated that TMB can also be a predictive biomarker for
ICI treatment and prognosis specifically in TNBC due to its high mutation
rates. TMB assessment is often performed using dedicated gene panels
like the Oncomine Tumor Mutation Load Assay (ThermoFisher®), SureSe-
lect XT HS custom TMB and human all Exon v6 panel (Illumina®), QIAseq
TMB panel, and NEOplus v2 RUO panel. Despite the limitations imposed
by the analyzed circumscribed genomic regions, these panels were opti-
mized to provide a reliable approximation of TMB. The rule of thumbs
suggests that targeted panel size should be at least 1.1 Mb in order to
provide an accurate estimate of the TMB [49]. Below the 1.1 Mb thresh-
old panels overestimate TMB assessment, especially in those cancer types
characterized by low or intermediate levels of TMB. A crucial aspect to
consider during TMB estimation is the nature of the preservation applied
to the tumor biopsy sample. Formalin-Fixed Paraffin-Embedded (FFPE)
tissues represent a staple of research and therapeutics in terms of biospec-
imen preservation. Eventually, FFPE preservation leads to degradation
of the DNA sequence in a process called deamination. Deamination in-
troduces artefacts that alter TMB estimate. TMB is emerging as valuable
biomarker for the stratification of ICI response. However, standardization
in its assessment is still lacking in terms of harmonization and normaliza-




The genomic landscape of
metastatic special types of breast
cancer
In this chapter, I focused on the study of four forms of special types of
breast cancer. I studied their genomic profiles in both primary and metastatic
forms and performed a comparison with a clinically matched cohort of
IDC-NSTs. The study allowed a re-analysis from a specific perspective
of the clinical cohort of the Razavi et al. study, available on cBioportal
(https://www.cbioportal.org) [56,57,58].
3.1 Introduction
Breast cancer (BC) is heterogeneous and comprises various entities with
divergent phenotype, biology, and clinical presentation [59,60]. There are
over 20 histologic special types of BC recognized by The World Health
Organization (WHO), accounting for 20% of all BCs [1]. Large sequenc-
ing studies have focused on invasive ductal carcinoma of no special type
(IDC-NSTs), the most common histologic form of BC [28, 60-65], and data
on the genomic landscape of histologic special types, particularly in the
metastatic setting, are scarce. These studies have shown that although
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the repertoire of somatic genetic alterations found in metastatic BCs is re-
markably similar to that of primary tumors, TP53, ESR1, ARID1A, ERBB2,
GATA3, KMT2C, NCOR1, NF1, and RB1 have been found to be signifi-
cantly more frequently mutated in metastatic disease [58,63,66]. In addi-
tion, ER+ metastatic BCs have been shown to more frequently display the
APOBEC mutagenesis and homologous recombination DNA repair de-
ficiency (HRD) processes than primary ER+ disease [63,66]. Massively
parallel sequencing studies by our group and others have revealed that
some histologic special types of BC are underpinned by highly recurrent
or even pathognomonic genetic alterations, including ETV6-NTRK3 fusion
gene in secretory carcinoma, and MYB/MYBL1 rearrangements or MYB
amplification in adenoid cystic carcinoma [60,67-68]. Furthermore, other
primary special types of BC, albeit not driven by pathognomonic fusion
genes or somatic mutations, have been found to harbor repertoires of ge-
netic alterations that differ from those of primary IDC-NST [25,70-77]. In
addition to CDH1 mutations, primary invasive lobular carcinomas (ILCs)
have been shown to display an enrichment in mutations affecting PIK3CA,
PTEN, TBX3, FOXA1, AKT1, ARID1A, ERBB2, and ERBB3, primary muci-
nous BCs harbor a lower frequency 1q gains, 16q losses, and PIK3CA and
TP53 mutations than ER+ HER2- IDC-NSTs matched by clinical charac-
teristics [70,78], micropapillary BCs display a repertoire of genetic alter-
ations comparable to that of common forms of BCs, with frequent muta-
tions in PIK3CA, TP53, GATA3, and MAP2K4 [79], and metaplastic BCs,
compared to triple-negative IDC-NSTs, more frequently harbor mutations
affecting genes of the PI3K/AKT/mTOR and canonical Wnt pathways
[77,80]. Here, through the reanalysis of targeted sequencing data gener-
ated with an FDA-approved multigene sequencing assay, we sought to de-
fine the repertoire of somatic genetic alterations of metastatic ILCs, mixed
mucinous, micropapillary, and metaplastic BCs, and determine whether
the landscape of somatic mutations and CNAs of metastatic special types
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of BC is distinct from that of their primary counterparts or of metastatic
IDC-NSTs.
3.2 Methods
3.2.1 Cases and study population
The study was approved by Memorial Sloan Kettering Cancer Center In-
stitutional Review Board as part of the project whose findings were ini-
tially published by Razavi et al. [58]. Informed consent was provided
in the original study by Razavi et al. [58]. Targeted massively parallel
sequencing data of primary and metastatic BCs were obtained from the
study by Razavi et al. [58]. All cases had been previously subjected to tar-
geted capture massively parallel sequencing using the MSK-IMPACT se-
quencing assay from the study by Razavi et al. [58]. Following the criteria
put forward by the WHO [1], 309 BCs were classified as of one of the spe-
cial histologic types included in this study: 259 were classified as classic
ILCs (n = 127 metastatic and n = 132 primary), 19 as mixed (i.e., >50% but
<90% mucinous component) mucinous carcinomas (n = 5 metastatic and
n = 14 primary), 20 as pure micropapillary carcinomas (n = 12 metastatic
and n = 8 primary), and 11 as metaplastic BCs (n = 6 metastatic and n =
5 primary). The initial diagnosis of a given special histologic type of BC
was retrieved from Razavi et al. [58], and cases for which the histologic
material of the sample subjected to sequencing was available (n = 265)
were reviewed centrally by a board-certified breast pathologist for diag-
nosis confirmation. Pleomorphic ILCs (metastatic, n = 6; primary, n = 8)
were excluded from further analyses. ER and HER2 status had been as-
sessed by immunohistochemistry and/or FISH, as previously described,
following the American Society of Clinical Oncology/College of Ameri-
can Pathologists guidelines [20,98].
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3.2.2 Comparison with common forms of breast cancer
For the comparison of non-synonymous TMB, FGA, frequency of non-
synonymous somatic mutations, and CNAs, metastatic BCs of special his-
tologic subtype were compared to those of IDC-NSTs included in the same
study [58], matched by age (20-year intervals), menopausal status, and
ER/HER2 status and to those of their primary counterparts. Metastatic
ILCs were matched to metastatic IDC-NSTs from the study by Razavi et al.
[58] previously subjected to MSK-IMPACT™at a 1:2 ratio, whereas mixed
mucinous BCs, micropapillary BCs, and metaplastic BCs were matched
to IDC-NSTs at a 1:3 ratio. No statistically significant differences were
observed in the therapy received prior to tumor sampling between the
metastatic BCs of special histologic types and metastatic IDC-NSTs matched
by clinicopathologic characteristics in the cohorts analyzed in this study.
Lollipop plots were produced using MutationMapper on cBioPortal, man-
ually curated and mutation types were color-coded as follows: splice-site
SNV (yellow), missense SNV (green), truncating SNV (black), in-frame in-
sertion/ deletion (brown), and hotspot mutation (orange).
3.2.3 Targeted massively parallel sequencing analysis
All samples included in this study were subjected to targeted sequencing
using the FDA-approved MSK-IMPACT™assay, as part of the study by
Razavi et al. [58]. Non-synonymous somatic mutations, amplifications,
and homozygous deletions were retrieved from the original study. The
raw MSK- IMPACT™sequencing data (FASTQ files) were reprocessed us-
ing our validated bioinformatics pipeline, as previously described [99,100],
for the inference of copy number gains and losses, and loss of heterozy-
gosity of genes targeted by somatic mutations and mutational signatures.
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Mutations affecting hotspot codons were annotated as described. Non-
synonymous TMB was calculated as the number of non-synonymous mu-
tations divided by the total genomic region assessed by MSK-IMPACT™,
per megabase. The FGA, defined as the number of base pairs which are
not copy neutral divided by the size of genome assayed, was retrieved
from the original study by Razavi et al. [58]. Mutational signatures were
defined using SigMA [87] using all synonymous and non-synonymous
somatic mutations of cases with at least five SNVs. Tumor purity was
inferred using FACETS [102]. The median tumor purity of special histo-
logic type BCs analyzed in study was 0.43 (95% CI=0.30-0.87). Of note, the
tumor purity of metastatic BCs of special histologic type (median = 0.47;
95% CI = 0.30-0.88) was higher than that of primary tumors (median =
0.39; 95% CI = 0.27-0.86; P = 1.4 × 10-2). As expected, the tumor purity of
metastatic ILCs (median = 0.48; 95% CI = 0.30-0.88) was higher than that of
primary ILCs (median = 0.38; 95% CI = 0.28-0.86; P = 1.1 × 10-3), whereas
no differences were observed in the comparisons between metastatic and
primary BCs of other histologic types analyzed in this study.
3.2.4 Assessment of TILs infiltration
Histologic assessment of TILs infiltration in primary and metastatic ILCs
with a sufficient number of SNVs ( 5) for accurate assessment of muta-
tional signatures by SigMA [87], and available H&E slides was performed.
The assessment of TILs infiltration was conducted following the guide-
lines described by the International TIL working group [103]. In brief,
following the examination of one representative section, the intra-tumoral
stromal area covered by mononuclear cells, including lymphocytes and
plasma cells, was recorded.
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3.2.5 Immunohistochemistry
Immunohistochemical analyses for MLH1, MSH2, MSH6, and PMS2 were
performed in a Bond-3 automated stainer platform (Leica Biosystems, Wet-
zlar, Germany). In brief, following antigen retrieval (ER2, Leica) for 30-
40min, tissue sections were incubated with monoclonal antibodies against
MLH1 (clone ES05; Leica Biosystems; dilution 1:500), MSH2 (clone G219-
1129; Cell Marque, Rocklin, CA; dilution 1:750), MSH6 (clone EP49; Dako,
Glostrup, Denmark; dilution 1:500), or PMS2 (clone A16.4; BD Biosciences,
Franklin Lakes, NJ; dilution 1:500) for 30 min. A polymer-based kit was
employed as secondary reagent (Leica Biosystems). Assessment of the
MLH2, MSH2, MSH6, and PMS2 expression was conducted by a board-
certified pathologist following the current standard practice.
3.2.6 Statistical analysis
Statistical analyses were conducted using R v3.1.2. Fisher’s exact tests
were employed for comparisons between categorical variables, and Mann-
Whitney U test were used for continuous variables. All tests were two-
sided and P values < 0.05 were considered statistically significant. We per-
formed multiple testing correction using the Benjamini–Hochberg proce-
dure to control for the false discovery rate (q values). To assess the mutual
exclusivity between ERBB2 and ESR1 mutations (hotspot mutations and
non-hotspot pathogenic mutations) in ER+ metastatic ILC and IDC-NST
using CoMEt [104]. The data generated and analyzed during this study




We reanalyzed the sequencing data corresponding to 309 samples of his-
tologic special types of BC reported by Razavi et al. [58], comprising 154
and 155 primary and metastatic BCs, respectively. A total of 127 primary
and 132 metastatic ILCs, 14 primary and five metastatic mixed mucinous
BCs, 8 primary and 12 metastatic micropapillary BCs, and 5 primary and 6
metastatic metaplastic BCs were included in this study. Most primary and
metastatic ILCs (95 and 81%), mixed mucinous BCs (79 and 100%), and
micropapillary BCs (63 and 75%) were ER+ HER2-, whereas 80 and 83%
of primary and metastatic metaplastic BCs were of triple-negative phe-
notype, respectively. We observed an enrichment of HER2-positive (7%)
and ER+ HER2- (12%) phenotypes in metastatic ILCs, as compared to pri-
mary ILCs (2%, each), whereas primary ILCs were more frequently of ER+
HER2- (95%) phenotype than metastatic ILCs (81%; P = 1.6 × 10-3).
3.3.2 Repertoire of somatic genetic alterations in primary
and metastatic ILCs
The ILCs included in this study were of classical type, characterized by a
uniform population of small to medium-sized tumors cells with a dysh-
esive growth pattern, usually arranged in strands and single files (Fig.
3.1a). We compared the repertoire of somatic genetic alterations between
primary and metastatic ILCs and observed that the non-synonymous tu-
mor mutation burden (TMB) of metastatic ILCs (median = 4.2, 95% CI =
0.8-20.5) was significantly higher than that of primary ILCs (median 2.5,
95% CI = 0.8-8.2, P = 3.9 × 10-7, Mann–Whitney U test; Fig. 3.1b). The
genes most frequently altered in metastatic ILCs (n = 132) overlapped
with those reported in primary tumors, including CDH1 (76%), PIK3CA
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(52%), TP53 (20%), ERBB2 (19%), FGF19, CCND1, FGF3, FGF4 (each, 17%),
and TBX3 (16%). Other frequently altered genes in metastatic ILCs in-
cluded ARID1A and FOXA1 (11%, each), MAP3K1 (10%), and PTEN (9%;
Fig. 3.1c). As compared to primary ILCs (n = 127), metastatic ILCs (n =
132) more frequently harbored genetic alterations affecting TP53 (20% vs
9%, respectively; P = 1.3 × 10-2), ESR1 (15% vs 2%, respectively; P=3×10-
4), FAT1 (9% vs 2%, respectively; P = 1.1 × 10-2), RFWD2 (8% vs 1%,
respectively; P = 5.4×10-3), and NF1 (8% vs 2%, respectively; P=1.9×10-
2; Fig. 3.1c). We also observed that ERBB2 was numerically more fre-
quently altered in metastatic ILCs than in primary ILCs (19% vs 12%, re-
spectively; P=1.2×10-1; Fig. 3.1c): 12% (16/132) of metastatic ILCs har-
bored ERBB2 mutations, 5% (6/132) ERBB2 gene amplification, and 2%
(3/132) harbored both ERBB2 mutations and gene amplification. In 10%
(13/132) of cases the ERBB2 mutations were hotspot mutations in the ki-
nase domain (Fig. 3.1c). Next, we compared the mutational repertoire of
metastatic ILCs (n = 132) to that of metastatic IDC-NSTs matched by age,
menopausal status, and ER/HER2 status at a 1:2 ratio (n=264). The non-
synonymous TMB of metastatic ILCs (median = 4.2, 95% CI = 0.8-20.5) was
significantly higher than that of metastatic IDC-NSTs matched by clini-
copathologic characteristics (median = 3.3, 95% CI = 0.8-12.8; P = 2.4 ×
10-6; Mann–Whitney U test; Fig. 3.1b). Compared to age, menopausal,
and ER/HER2 status-matched metastatic IDC-NSTs (n = 264), metastatic
ILCs (n = 132) harbored a significantly higher frequency of genetic alter-
ations affecting CDH1 (76% vs 3%, respectively; P = 9.8 × 10-54),PIK3CA
(52% vs 34%, respectively; P = 7 × 10-4), ERBB2 (19% vs 11%, respectively;
P=2.8×10-2), TBX3 (16% vs 6%, respectively; P=3.6×10-3), NCOR (9% vs
3%, respectively; P = 1 × 10-2), RFWD2 (8% vs 1%, respectively; P = 6 ×
10-4), and a significantly lower frequency of genetic alterations affecting
TP53 (20% vs 34%, respectively; P = 3.3 × 10-3), ESR1 (15% vs 25%, respec-
tively; P = 2.8 × 10-2), and GATA3 (7% vs 20%, respectively; P = 4 × 10-4)
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among others (Fig. 3.1c). Most ERBB2 mutations identified in metastatic
ILCs (n = 59%), primary ILCs (67%), and metastatic IDC-NSTs (45%) af-
fected hotspot loci (Fig. 3.1d). Notably, the L755S ERBB2 hotspot muta-
tion was the most frequent in both metastatic (8/22; 36%) and primary
ILCs (4/12; 33%; Fig. 3.1d), as previously reported [25]. This mutation,
however, accounted for only 17% (2/12) of the ERBB2 mutations detected
in metastatic IDC-NSTs matched by clinicopathologic characteristics (Fig.
3.1d). Of note, we did not identify differences in pre-biopsy therapy of pa-
tients with metastatic ILCs harboring L755S ERBB2 mutations, that could
account for the observed enrichment. Given the role of ESR1 mutations
and ERBB2 mutations in endocrine therapy resistance in ER+ metastatic
BCs [34,58,81-84], we sought to investigate their mutual exclusivity in ER+
metastatic ILCs (n=113) and IDC-NSTs (n=226). We observed that hotspot
mutations or pathogenic mutations affecting ESR1 and ERBB2 were mutu-
ally exclusive in metastatic ILCs (P = 4.8 × 10-2; CoMEt; Fig. 3.1e). These
findings are consistent with those reported by Razavi et al. [58], where
ESR1 and ERBB2 mutations were found to be mutually exclusive in ER+
HER2- BCs regardless of their histologic subtype. Hence, akin to common
cancer types of BC, ESR1, and ERBB2 mutations are present in a mutually
exclusive manner in metastatic ILCs, and may constitute mechanisms of
resistance to endocrine therapy [34,58,81-84]. To define the repertoire of
somatic genetic alterations present in ILCs, we combined the primary and
metastatic ILCs of this study in one cohort (n = 259), and compared them
to combined primary and metastatic IDC-NSTs, matched to the ILCs ac-
cording to age, menopausal status, ER/HER2 status, and sample type at a
2:1 ratio (n = 518). This analysis revealed differences consistent with our
findings when primary and metastatic ILCs were compared to IDC- NST
separately. Combined primary and metastatic ILCs (n = 259) displayed a
higher non-synonymous TMB (P = 1.8 × 10-7) than combined primary and
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metastatic IDC-NSTs (n = 518). In addition, as compared to combined pri-
mary and metastatic IDC-NSTs, combined primary and metastatic ILCs
harbored a higher frequency in genetic alterations affecting CDH1 (79%
vs 3%; P=1.0×10-116), PIK3CA (54% vs 37%; P= 5.3 × 10-6), ERBB2 (15%
vs 8%, P = 1.6 × 10-3), TBX3 (13% vs 6%; P = 1.4 × 10-3), ARID1A (10%
vs 5%; P = 3.4 × 10-2), NCOR1 (8% vs 4%, P=4×10-2), RUNX1 (7% vs 3%:
P=2.7×10-2), and RFWD2 (5% vs 1%, P=7×10-4), and a lower frequency of
genetic alterations affecting TP53 (14% vs 33%; P = 2.6 × 10-8), ESR1 (9%
vs 15%, P=2.2×10-2), and GATA3 (5% vs 19%; P=1.2×10-8).
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FIGURE 3.1 (previous page): Repertoire of genetic alterations
in primary and metastatic invasive lobular carcinomas of
the breast. A) Representative photomicrographs of a H&E-
stained primary breast invasive lobular carcinoma (pILC; left)
and a metastatic lobular carcinoma (mILC) involving ovarian
stroma (right). Scale bars, 50 µm. B) Boxplots depicting the
non-synonymous tumor mutation burden of mILCs (n = 132),
metastatic invasive ductal carcinomas of no special type matched
by age, menopausal status, and estrogen receptor (ER)/HER2 sta-
tus (mIDC-NSTs; n = 264), and pILCs (n = 127). Mann–Whitney
U test, two-tailed. C) Comparison of the cancer genes most fre-
quently affected by non-synonymous somatic mutations, amplifi-
cations, or homozygous deletions in mILCs (n = 132), metastatic
age-, menopausal status-, and ER/HER2 status- matched mIDC-
NSTs (n = 264) and pILCs (n = 127). Cases are shown in columns
and genes in rows. Mutation types are color-coded according to
the legend. ER/HER2 status are shown on phenobars (top). *P
< 0.05, **P < 0.01, ***P < 0.001; Fisher’s exact test, two-tailed.
D) Schematic representation of the protein domains of ERBB2 and
the somatic mutations in metastatic mILCs (n=132), mIDC-NSTs
matched by clinicopathologic characteristics (n = 264) and pILCs
(n = 127). Mutations are color-coded according to the legend, and
their frequency is represented by the height of each lollipop (y-axis).
E) Mutual exclusivity analysis of ESR1 and ERBB2 hotspot, and
oncogenic/likely oncogenic mutations in ER+ mILCs (n = 113)
and mIDC-NSTs (n = 226). Hom. homozygous, Indel inser-
tion/deletion, LOH loss of heterozygosity, SNV single nucleotide
variant.
3.3.3 Repertoire of somatic genetic alterations in primary
and metastatic mixed mucinous BCs
The mixed mucinous BCs analyzed in this study were characterized by
areas of tumor cells floating in lakes of mucin admixed with areas of IDC-
NST (Fig. 3.2a, b). Metastatic mixed mucinous BCs harbored a signifi-
cantly higher non-synonymous TMB (median = 4.2, 95% CI = 1.7-5.8) than
primary mixed mucinous BCs (median=0.8, 95% CI=0.8-2.2, P=1.5×10-3,
Mann–Whitney U test), but comparable to that of metastatic IDC-NSTs
matched according to clinical features (median = 3.3, 95% CI = 0.8-6.4,
P =6×10-1; Fig. 3.2b). The repertoire of genetic alterations of metastatic
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mixed mucinous BCs (n = 5) in this study was similar to that of primary
mucinous/mixed BCs [70,71,85]. Although based on a small number of
cases, this analysis revealed that the genes recurrently altered in metastatic
mixed mucinous BC and not altered in primary mixed mucinous BCs of
this study, and pure/mixed mucinous BCs reported by our group and oth-
ers [70,71,85] included ESR1 (60% vs 0%, respectively; P = 1 × 10-2) and
NCOR (40% vs 0%, respectively; P = 6 × 10-2; Fig. 3.2c). In agreement
with previous studies [86], compared to metastatic IDC-NSTs matched by
clinical features, metastatic mixed mucinous BCs harbored a higher fre-
quency of 11q13.3 amplification (60% vs 7%, respectively; P = 3.2 × 10-2;
Fig. 3.2c).
3.3.4 Repertoire of somatic genetic alterations in primary
and metastatic micropapillary BCs
The micropapillary BCs included in this study were characterized by morula-
like clusters of tumor cells without a fibrovascular core within pseudo-
vascular spaces (Fig. 3.3a). We observed no significant differences in the
non-synonymous TMB of metastatic micropapillary BCs (median = 1.2,
95% CI = 0.8-4) compared to that of primary micropapillary BCs (median
= 1.2, 95% CI = 0.8-4; P = 1.3 × 10-1) or to that IDC-NSTs matched by clin-
ical features (median = 3.3, 95% CI = 0.8-11.7; P = 3.9 × 10-1). In a way
akin to IDC-NSTs, the most frequently altered genes in metastatic and pri-
mary micropapillary BCs were PIK3CA (58 and 25%) and TP53 (42 and
38%). Recurrent alterations in ESR1 (25%), KDR, ARID1B, and ATR (17%,
each) were restricted to metastatic micropapillary BCs (Fig. 3.3b). On the
other hand, MYC gene amplification was more frequent in primary than
in metastatic micropapillary BCs (38% vs 0%, respectively; P = 4.9 × 10-2;
Fig. 3.3b).
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FIGURE 3.2: Repertoire of genetic alterations in primary
and metastatic mixed mucinous breast cancers. A) Repre-
sentative photomicrographs of a H&E-stained primary mixed mu-
cinous breast cancer (pMUC; top), and a metastatic mixed muci-
nous breast cancer (mMUC) involving liver (bottom). Scale bars
in a, 100 µm (top) and 50 µm (bottom). B) Boxplots depicting
the non-synonymous tumor mutation burden in mMUCs (n = 5),
metastatic invasive ductal carcinoma of no special type matched
by age, menopausal status, and estrogen receptor (ER)/HER2 sta-
tus (mIDC-NST; n = 15), and pMUCs (n = 14). Mann–Whitney
U test, two-tailed. C) Comparison of the cancer genes most fre-
quently affected by non- synonymous somatic mutations, am-
plifications, or homozygous deletions in mMUCs (n=5), in age-
, menopausal status-, and ER/HER2 receptor status-matched
mIDC-NSTs (n = 15), and in pMUCs (n = 14). Cases are shown
in columns and genes in rows. Mutation types are color- coded
according to the legend. ER/HER2 status are shown on pheno-
bars (top). *P < 0.05; Fisher’s exact test, two-tailed. Indel inser-
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